Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Wealth planning tools are essential for financial success. Discover resources that can help you achieve your financial aspirations.
28,655 articlesA trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
CF Industries climbs as global nitrogen supply tightens and European disruptions spill over into North American marke...
A Middle East crisis sent oil prices higher and spotlighted a rapid shift to electric vehicles. New data show the wor...
Two Harbors Investment will terminate its merger with UWM and accept an all-cash bid from CrossCountry worth roughly ...
Dream Finders' unsolicited cash offer values Beazer at about $704 million, sparking a public contest as U.S. homebuil...
Target rolls out a broad turnaround, including redesigned carts and a baby concierge service, but investors question ...
As the Fed stays steady on rates, investors debate whether crypto should be bought before or after the next rate cut....
NOWPayments launches a zero-fee, instant crypto payout platform built for high-volume partners, delivering 1-second s...
The Columbia Research Enhanced Real Estate ETF (CRED) yields about 3.6% via pass-through REIT dividends. The fund’s i...
The U.S. DOJ opened the door for Paramount Skydance to acquire Warner Bros. Discovery in a $110 billion deal, signali...
As of June 22, 2026, Vanguard’s international dividend ETF is delivering a higher yield and stronger year-to-date per...
U.S. equity markets tumbled as traders priced in a looming memory supply crisis in chipmakers, triggering a broad tec...